Evaluation of comorbidity burden on disease progression and mortality in patients with interstitial pneumonia with autoimmune features: A retrospective cohort study
CCI and RDCI may be useful tools in assessing prognosis in patients with IPAF in terms of both lung disease progression and mortality. Prospective studies are needed to further evaluate the performance of CCI and RDCI and the impact of optimizing comorbid conditions that may mitigate poor outcomes among patients with IPAF.
Authors
- Traci N. Adams (ORCID: https://orcid.org/0000-0002-5834-459X)
- Elena K. Joerns (ORCID: https://orcid.org/0000-0001-7089-9152)
- Una E. Makris (ORCID: https://orcid.org/0000-0003-4750-0777)
- Michelle A. Ghebranious
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- VA North Texas Health Care System (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1371/journal.pone.0316762
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Pfizer
- National Institute on Aging